Discover why Mirum Pharmaceuticals is a growth opportunity with billion-dollar pipeline potentials, near-term catalysts, and ...

Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...

Royalty Pharma Plc engages in the provision of drug ... Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta ...

French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on genetic ...

Pharma Science™, the Indian Ayurveda, a trailblazer in the Ayurvedic healthcare industry, is redefining natural wellness ...

Alnylam Pharmaceuticals Inc (ALNY) reports strong financial performance with significant growth in TTR franchise and ...